Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
Realize the True Potential of RNA Targeting Small Molecules through Optimizing Design & Technology of Improved Assays & Screens for Efficient Identification of Potent, Selective & Biologically Relevant RNA Target
CANCELLED
CANCELLED
Welcome to the RNA Assay Development & Screening Summit: Revolutionizing
RNA-Targeted Drug Discovery with Robust Assays & Screens
There has been many exciting investments and advancements in the field, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and screening methods for understanding the RNA target structure as well as the mechanism of action of the small molecule drugs.
Join 80+ technical experts from the likes of AstraZeneca, Atavistik Bio, AbbVie, NextRNA Therapeutics, Expansion Therapeutics, Accent Therapeutics and more at the RNA Assay Development & Screening Summit to discuss assays and screening methods for understanding the true potential and mechanism of RNA-targeting small molecules to find treatments to currently ‘undruggable’ targets.
Previous Attending Companies
Partners
